文献速递临床生化临床免疫质量管理与危急值

欧洲生物学变异研究(EuBIVAS)总结报告

The European Biological Variation Study (EuBIVAS): a summary report.
PubMed 文献 · Clin Chem Lab Med · 2021-05-31

欧洲临床化学与实验室医学联合会(EFLM)生物学变异工作组为获得高质量生物学变异(BV)数据,开展了多中心欧洲生物学变异研究(EuBIVAS)。该研究从6个欧洲中心招募91名表观健康个体,连续10周采集血清/血浆样本,采用严格的分析前和分析方案,使用多种分析系统检测,已为80个不同检测项目提供BV估计值。许多项目的BV估计值低于先前报道,影响派生分析性能规范和参考变化值。

要点

  • EuBIVAS为80个检测项目提供了高质量BV数据,其中10个项目此前无可用BV数据。
  • 许多项目的BV估计值低于先前报道,影响分析性能规范和参考变化值。
  • 研究采用严格的分析前和分析方案,并使用CV-ANOVA或贝叶斯模型确定BV估计值及95%CI。

核心结论

  • EuBIVAS已为广泛检测项目提供高质量BV数据,许多项目的BV估计值低于先前报道,影响派生分析性能规范和参考变化值。

研究设计与样本

  • EuBIVAS为多中心研究,从6个欧洲中心招募91名表观健康个体,连续10周采集血清/血浆样本,采用严格的分析前和分析方案,使用Siemens ADVIA 2400、Cobas Roche 8000、c702和e801、ACL Top 750、IDS iSYS或DiaSorin Liaison等分析系统检测。

主要发现

  • EuBIVAS已为80个不同检测项目提供BV估计值。
  • 10个检测项目(非HDL胆固醇、S100-β蛋白、神经元特异性烯醇化酶、可溶性转铁蛋白受体、完整成纤维细胞生长因子-23、未羧化未磷酸化基质Gla蛋白、人附睾蛋白-4、游离、结合和%游离前列腺特异性抗原)在EuBIVAS之前无可用BV数据。
  • 肌酐和肌钙蛋白I的BV数据分别使用两种分析方法获得。
  • 许多检测项目的BV估计值低于先前报道。

关键数值与推荐

  • 使用CV-ANOVA(经异常值、同质性和趋势分析后)或贝叶斯模型确定BV估计值及95%CI。

临床怎么用

  • EuBIVAS提供的BV数据可用于派生分析性能规范和参考变化值,许多项目BV估计值低于先前报道,可能影响相关规范的设定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biological variation (BV) data have many important applications in laboratory medicine. Concerns about quality of published BV data led the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) 1st Strategic Conference to indicate need for new studies to generate BV estimates of required quality. In response, the EFLM Working Group on BV delivered the multicenter European Biological Variation Study (EuBIVAS). This review summarises the EuBIVAS and its outcomes. Serum/plasma samples were taken from 91 ostensibly healthy individuals for 10 consecutive weeks at 6 European centres. Analysis was performed by Siemens ADVIA 2400 (clinical chemistry), Cobas Roche 8000, c702 and e801 (proteins and tumor markers/hormones respectively), ACL Top 750 (coagulation parameters), and IDS iSYS or DiaSorin Liaison (bone biomarkers). A strict preanalytical and analytical protocol was applied. To determine BV estimates with 95% CI, CV-ANOVA after analysis of outliers, homogeneity and trend analysis or a Bayesian model was applied. EuBIVAS has so far delivered BV estimates for 80 different measurands. Estimates for 10 measurands (non-HDL cholesterol, S100-β protein, neuron-specific enolase, soluble transferrin receptor, intact fibroblast growth-factor-23, uncarboxylated-unphosphorylated matrix-Gla protein, human epididymis protein-4, free, conjugated and %free prostate-specific antigen), prior to EuBIVAS, have not been available. BV data for creatinine and troponin I were obtained using two analytical methods in each case. The EuBIVAS has delivered high-quality BV data for a wide range of measurands. The BV estimates are for many measurands lower than those previously reported, having an impact on the derived analytical performance specifications and reference change values.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Carobene A, Aarsand AK, Bartlett WA, et al. The European Biological Variation Study (EuBIVAS): a summary report. Clin Chem Lab Med. 2021. PMID: 34049424. doi:10.1515/cclm-2021-0370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。